Interventional News’ most read stories in September included first data releases from the this year’s Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2023 annual meeting (9–13 September, Copenhagen, Denmark) such as STRIKE-PE results; Laminate Medical announce FDA approval of flagship VasQ External Vascular Support device and a multi-society update on guidelines for varicose vein management.
Presenting data from the MOTIV bioresorbable scaffold (Reva Medical) below-the-knee (BTK) trial during Saturday’s FIRST@CIRSE session at CIRSE 2023 annual meeting (9–13 September, Copenhagen, Denmark), Thomas Rand (Klinikum Floridsdorf, Vienna, Austria) underlined the “promising future applications” of the device for the treatment of BTK arteries.
Find out how, by taking away the difficulties associated with freehand alignment and targeting, Micromate helps physicians focus on improving reproducibility, speeding up the procedure, reducing radiation dose, and deploying the system even for complex indications.
Presenting real-world population data in patients with pulmonary embolism (PE), John Moriarty (University of California, Los Angeles Medical Center, Los Angeles, USA) demonstrated results from the STRIKE-PE study at this year’s CIRSE 2023 annual meeting.
Mishal Mendiratta-Lala (University of Michigan, West Bloomfield, USA) presented “much awaited” data from the #HOPE4LIVER trial at CIRSE 2023, which demonstrated the “successful, non-invasive destruction” of liver tissue using hepatic histotripsy.
Laminate Medical Technologies has announced their flagship device, the VasQ External Vascular Support, has been cleared by the US Food and Drug Administration (FDA) for use to create arteriovenous fistulas (AVFs) for dialysis access.
Tze Tec Chong (Singapore General Hospital, Singapore) presented results from the PRISTINE registry at CIRSE 2023, which aimed to investigate the performance and safety of the Selution SLR (MedAlliance) sirolimus-eluting balloon (SEB) for the treatment of complex occlusive lesions in chronic limb threatening ischaemia (CLTI) patients in Singapore.
LimFlow, a developer of minimally-invasive technologies for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), has announced that the US Food and Drug Administration (FDA) has approved the LimFlow system to help people with CLTI who have no other suitable endovascular or surgical treatment options and are facing major amputation.
In sessions dedicated to radiation protection at CIRSE 2023, contemporary risk management strategies for staff and patients, and challenges faced by interventional radiologists in the developing world were among key takeaways across Sunday and Monday.
Biotronik has announced the two-year results from the BIOLUX P-III BENELUX all-comers registry, presented by principal investigator Frank Vermassen (Ghent University, Gent, Belgium) at CIRSE 2023.
The Society for Vascular Surgery (SVS), American Venous Forum (AVF), and American Vein and Lymphatic Society (AVLS) have released the second and final part of new guidelines for the management of varicose veins of the lower extremities. The recommendations, which update the 2011 SVS and AVF guidance on the topic, were published online ahead of print in the Journal of Vascular Surgery: Venous and Lymphatic Disorders (JVS-VL).